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BRETOrexin-A and Orexin-B play important roles in many physiological processes in which Orexins orchestrate
diverse downstream effects via two G-protein coupled receptors: Orexin1R and Orexin2R. Two alternative C-
terminus splice variants of the mouse Orexin receptors mOX2αR and mOX2βR have recently been identiﬁed.
This study explored the possibility of heterodimerization between mOX2αR and mOX2βR, and investigated
novel signal transduction characteristics after stimulation. The dimerization of mOX2αR and mOX2βR was
conﬁrmed by BRET and co-immunoprecipitation assays. Meanwhile, in HEK293 cells, co-expression of
mOX2αR and mOX2βR resulted in a strengthened increase in activation of ERK1/2, with maximal activation at
5 min and 100 nM. Furthermore, heterodimerization also elicits stronger intracellular Ca2+ elevation after
Orexin(s) stimulation, followed by a slower decline in intracellular Ca2+ to a steady endpoint. Protein Kinase C
Inhibitor signiﬁcantly inhibited these downstreameffects. In addition, the cAMP response element reporter activ-
itieswere signiﬁcantly reduced,whereas the serum response element luciferase and the T-lymphocyte activation
of nuclear factor-responsive element reporter activity were signiﬁcantly up-regulated after Orexin(s) stimula-
tion. Besides, Orexin-A/-B induced a signiﬁcantly higher rate of HEK293 cell proliferation in cells co-expressing
mOX2αR/mOX2βR compared to the control group. Taken together, we provide conclusive evidence that
mOX2αR can forma functional heterodimerwithmOX2βR and this leads to increased PKC and decreased protein
kinase A activity by ERK signal pathway leading to a signiﬁcant increase in cell proliferation. The nature of this
signaling pathway has signiﬁcant implications for the role of Orexin in the regulation of physiological processes
including the homeostasis of feeding.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
G protein-coupled receptors (GPCRs), containing 7 trans-membrane
helices, are a family of receptors at the heart of many processes in cell
signaling [5]. GPCRs play an important role in signal recognition and
transduction, regulation of various physiological processes, making
them important drug targets [1]. Recently, it became evident that
these receptors function asmonomers or oligomers. Among such recep-
tor complexes, homodimeric or heterodimeric interactions between
protomers can occur [34].
In recent years, a large number of studies have shown that GPCR di-
merization is very important for receptor function including agonist and
antagonist afﬁnity, efﬁciency, transport and signal transduction speci-
ﬁcity [6]. The orexigenic peptides, Orexin-A andOrexin-B (HCRT, ofﬁcial
gene symbol) derive from a common precursor by protease hydrolysis,86 537 3616777.
and Vascular Health, Warwick
: +44 2476968643.
.Chen@warwick.ac.uk (J. Chen).
ights reserved.and share 46% amino acid sequence homology [41]. Orexins have been
reported to play an important role in numerous physiological processes,
such as stimulating feeding and energy homeostasis [23] and enhancing
gastric acid secretion [44] and glucocorticoid release [25,33] and is
involved in the sleep–wake cycle [9]. We have also demonstrated that
human Orexin type 2 receptor (OX2R) regulation is highly complex,
involving a proximal PKA/PKC regulated promoter and a distal promot-
er regulating tissue speciﬁc expression of alternate transcripts which in
turn post-transcriptionally regulate receptor levels [12]. Similarly, in
mice Orexins exert divergent actions, such as regulating feeding and
metabolism and lowering blood glucose, and their expression is altered
by food deprivation [31,48].
Orexin-A and -B orchestrate their physiological effects by binding
and activating two types of GPCRs, named Orexin type 1 receptor
(OX1R) and OX2R which have 64% sequence homology at the amino
acid level [16,41]. Studies have demonstrated that OX2R has equal afﬁn-
ity for both Orexin-A and Orexin-B, while OX1R has a ten-fold greater
afﬁnity for Orexin-A than for Orexin-B [2,38,41]. In mice, the C terminal
of mouse OX2R alternatively splice to create two different receptors:
mOX2αR and mOX2βR [10,11]. mOX2αR is composed of 7 exons and
6 introns which encode protein with 443 amino acids, and mOX2βR
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receptors. The major difference between two receptors locates at C-
terminus where mOX2αR has 17 more amino acids than mOX2βR.
Studies from our group showed that mOX2βRwaswidely expressed
in the brain, spleen, lung, liver, muscle, kidney and testis, but mOX2αR
was not detected in the liver and kidney. Furthermore, food deprivation
resulted in gene expression of mOX2βR with a greater increase in the
hypothalamus. We have also demonstrated differential expressions of
mOX2αR and mOX2βR in the mouse brain [10]. Our experiments
showed that although there were no differences in afﬁnity of Orexin-A
and Orexin-B to the two receptors, interaction between Orexin-B and
mOX2βR appeared to give a higher maximum IP response than
mOX2αR. These experiments showed that the two receptors have dif-
ferent functions and play important physiological roles [11].
Using a yeast two-hybrid screening strategy and co-
immunoprecipitation(Co-IP)experiments,DavidDuguayetal.found
interactionsbetweenOrexin1RandthedyneinlightchainsTctex-type
1and3(Dynlt1,Dynlt3)[17].ItwasreportedthatOrexin1RandCannabi-
noidCB1receptoralsogenerateheteromultimerizationtogether[46].
WehypothesizedthereforethatthetwomOX2αRandmOX2βRvariants
canheterodimerizeandsubsequentlyaffectsignalingpathways.Fur-
thermore,weexploredwhetherthesignaltransductionafterOrexin-
A/-Bstimulationwouldbealteredbyheterodimerization.
2. Materials and methods
2.1. Materials
Human Orexin-A and Orexin-B were obtained from Phoenix Phar-
maceuticals (Phoenix Pharmaceuticals, Europe GMBH, and Germany).
The mammalian expression vectors pcDNA3.1 (−), Lipofectamine-
2000 and Geneticin (G-418 sulfate) were obtained from Invitrogen
(Invitrogen Ltd, Paisley, UK). Protein Kinase C Inhibitor (Ro-31-8220)
and phospholipase C (PLC) inhibitor U-73122 were purchased from
Sigma (Sigma-Aldrich Company, UK). Anti-Orexin Receptor 2 antibody
(ab52659) and anti-β-actin antibody (ab8229) was purchased from
Abcam Company. Phospho-ERK1/2 (Thr202/Tyr204) antibody, ERK1/2
antibody, anti-Myc antibody, anti-HA antibody, monoclonal Myc-
antibody conjugated with Alexa-Fluor®594 (red) and secondary anti-
bodies conjugated Alexa Fluor 488 (green)were supplied by Cell Signal-
ing Technology Inc. (Danvers, MA, USA). Polyclonal horseradish
peroxidase-conjugated goat anti-rabbit immuno-globulins/HRP was
obtained from ZSGB-BIO (Zhong Shan Gold Bridge Biology Corporation,
Beijing China).
2.2. Plasmid constructs
The pcDNA3.1-mOX2αR and pcDNA3.1-mOX2βR plasmids were
constructed as previously described [11]. To construct HA-tagged
mOX2αR (HA-mOX2αR) and Myc-tagged mOX2βR (Myc-mOX2βR),
the incorporation of sequences encoding the hemagglutinin (HA) epi-
tope tag (YPYDVPDYA) and the Myc epitope tag (EQKLISEEDL) into
mOX2αR or mOX2βR genes, respectively, was performed by PCR. The
puriﬁed full-length cDNA of HA-mOX2αR and Myc-mOX2βR was
digested and cloned into pcDNA3.1 plasmid. Rluc-mOX2αR was made
using the sense primer: 5′-ATGTCCAGCACCAAACTGGAGG-3′, and anti-
sense primer 5′-CCAGTTTTGAAGCGGTCCTGC-3′ and cloned into
pRluc-N1 (BioSignal Packard, Inc., Montreal, Canada); EGFP-mOX2βR
wasmade using 5′-ATGTCCAGCACCAAACTGGAGG-3′ as forward primer
and 5′-GACCTCCAGCCAGGTGGACAGG-3′ as reverse primer and cloned
into the pEGFP-N1 (Clontech, USA). The resulting construct was con-
ﬁrmed by commercial sequencing.
The plasmids, pSRE-Luc (which were used in serum response
element (SRE) detecting) and pCRE-Luc (which were used in cAMP
response element (CRE) detecting), were purchased from Stratagene
(La Jolla, Cal, USA). And the other plasmids, pGL4.30 (which wereused in nuclear factor of activated T-cell response element (NFAT-RE)
detecting) and pRL-Tk were purchased from Promega (Madison, WI,
USA).
The stably transfected cell lines HEK293-mOX2αR/mouse kappa
opioid receptor (mKOR) acted as controls since mOX2αR cannot form
heterodimer with mKOR.
2.3. Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were cultured in MEM
(Hyclone, China) with 10% heat inactivated fetal bovine serum, 100 U/ml
penicillin, and 100 μg/ml streptomycin at 37 °C in a 5% CO2 incubator.
For the generation of cell lines stably expressing OX2αR (HEK293-
mOX2αR cells), OX2βR (HEK293-mOX2βR cells), and OX2αR/OX2βR
(HEK293-mOX2αR/mOX2βR cells), HEK293 cells were transfected with
the pcDNA3.1-mOX2αR plasmid, pcDNA3.1-mOX2βR plasmid and
pcDNA3.1-mOX2αR/pcDNA3.1-mOX2βR plasmids, respectively, using Li-
pofectamine 2000 (Invitrogen, USA) according to the manufacturer's in-
structions. 48 h after transfection, the culture media were removed and
were replaced with culture media containing G418 (0.5 mg/ml) (Gibco,
Invitrogen, Paisley, UK). Individual clones that survived were subcultured
in the selectiveprocess for eightweeks.mOX2αRandmOX2βRexpression
was assessed byRT-PCR. For someexperiments, transient transfectionwas
performed using Lipofectamine-2000 according to the manufacturer's
protocol.
2.4. Single cell PCR
The Neuro-2a (mice neuroblastoma; ATCC) cell's cytoplasm was
harvested via the patch clamp micro-electrode pipette, without losing
the gigaseal to prevent contamination with extracellular ﬂuid. Subse-
quently, the pipette contents were expelled into a sterile 0.5 ml tube.
The single-cell cDNA synthesis was performed as previously described
[2]. A minus-reverse transcriptase control was introduced to avoid the
possibility of gDNA. The sets of primers used for RT-PCR ampliﬁcation
were mOX2αR and mOX2βR, sense primer 5′-GGTTCATCATCGCCAA
GGAGAC-3′; antisense prime for mOX2αR: 5′-TGAGTCGGGTATCCTC
ATCATAG-3′, and antisense primer for mOX2βR: 5′-GTGAGATTCCAT
AAGGATGCTC-3′. The mouse GAPDH gene was used as an endogenous
control and ampliﬁed with the following primer pairs: sense primer:
5′-ATGGCCTTCCGTGTTCCTAC-3′; antisense primer: 5′-GCCTGCTTCACC
ACCTTCTT-3′.
The predicted size of PCR products is 215 and 265 bp for mOX2αR
andmOX2βR, respectively. ThemouseGAPDHPCRproducts are 104 bp.
All PCR reactions were carried out using Taq DNA Polymerase
(GIBCO BRL, Paisley, UK). cDNAs were ampliﬁed at 94 °C (45 s); 58 °C
(45 s); and 72 °C (1 min); in a total of 35 cycles with a ﬁnal extension
step at 72 °C for 10 min. The PCR products were analyzed on a 1.0% aga-
rose gel with 1 μg/ml ethidium bromide.
2.5. Immunostaining and confocal microscopy
HEK293 cells were grown on glass coverslips pretreated with a
0.1 mg/ml solution of poly-D-lysine in 6-well plates. Forty-eight hours
after co-transfection with HA-mOX2αR and Myc-mOX2βR, cells were
ﬁxedwith 4% paraformaldehyde in PBS and nonspeciﬁc bindingwas re-
duced by incubating cells with 3% bovine serum albumin in PBS-Triton
X-100 (0.01%) for 1 h at room temperature. Cells were washed three
times for 5 min with PBS-Triton X-100 (0.01%) then incubated with
speciﬁc primary antibody (monoclonal Myc-antibody conjugated with
Alexa-Fluor®594 (red) and anti-HA antibody) (Cell Signaling Technolo-
gy, Danvers, USA) overnight at 4 °C. Cells were then washed with PBS-
Triton X-100 as before and incubatedwith Alexa Fluor 488 (green) con-
jugated secondary antibodies (1:400) (Molecular Probes, Invitrogen)
for 1 h at room temperature. Coverslips were washed with PBS on
microscope slides and mounted in Vectashield Mounting Medium
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Peterborough, UK). Cells were examined under an oil immersion objec-
tive (×63) using a Leica model DMRE laser scanning confocal Micro-
scope (Leica, Milton Keynes, UK).
2.6. Enzyme-Linked Immunosorbent Assay (ELISA)
One day before transfection, HEK-293-cells were plated at a density
of 2 × 105 cells per well in 96-well plates. Transient transfection was
performed with HA-mOX2αR and Myc-mOX2βR and co-transfected
HA-mOX2αR/Myc-mOX2βR, respectively, using Lipofectamine 2000
(Invitrogen, USA) according to the manufacturer's instructions. After a
further 24 h, cells were ﬁxed using 4% paraformaldehyde in PBS
(30 min at room temperature). After ﬁxation, the cells were washed
three times with PBS, and the nonspeciﬁc binding sites were blocked
with blocking buffer (3% dry milk). Cells were incubated with the
primary rabbit polyclonal anti-HA antibody or anti-Myc antibody (cell
signal) overnight at 4 °C, subsequently washed with PBS three times
and then further incubated with a peroxidase conjugated goat/rabbit
secondary antibody in DMEM for 1 h at 37 °C. Primary antibodies were
used as 1:500, and secondary antibodies as 1:2000 dilutions in blocking
buffer. The ﬁnal substrate (200 μl) 3,3′,5,5′-tetramethylbenzidine
(Sigma-Aldrich) was added and incubated for 30 min at 37 °C and the
enzymatic reaction stopped with 50 μl of 2 N H2SO4 solution. Colorimet-
ric reaction was measured using an iMark™Microplate reader (Bio-Rad,
USA) at 450 nm wavelength.
2.7. Co-immunoprecipitation and immunoblotting
Co-immunoprecipitationwas performed as previously described [7].
HEK293 cells in 60-mm dishes were co-transfected with HA-mOX2αR/
Myc-mOX2βR. 48 h later, the cells were lysed with 1% RIPA Lysis Buffer
(Beyotime, Jiangsu, China). After clariﬁcation by centrifugation at 4 °C
for 30 min at 12,000 rpm, 500 μl cell lysates were incubated with
20 μl of HA-conjugated beads (Cell Signaling Technology, Danvers,
USA) for 4 h with gentle rotation at 4 °C. The beads were washed 4
times with the cell lysis buffer and precipitates were eluted with
2×SDS-PAGE sample buffer, and then analyzed by western blot for
anti-Myc and anti-HA (Cell Signaling Technology, Danvers, USA) immu-
noreactivity, respectively.
2.8. BRET experiment
HEK293 cells were transiently cotransfected with vectors encoding
Rluc fusion or EGFP fusion proteins. Twenty-four hours after transfec-
tion, cells were detached with 0.05% trypsin–0.53 mM EDTA, and cells
at a density of 2 × 105 cells per well were distributed in a 96-well mi-
croplate (Corning 3600, white opaque plates). After another 24 h, cells
were washed twice in PBS and resuspended in PBS containing 0.5 mM
MgCl2 and 0.1% glucose. Coelenterazine h substrate was added at a
ﬁnal concentration of 5 μM in the total volume of 50 μl/well. When ap-
propriate, cells were pretreated with Orexin-A or Orexin-B at 100 nM
ﬁnal concentration as indicated for 15 min prior to addition of substrate.
Readings were then immediately performed at 37 °C and at 0.5 s inter-
vals and during several minutes using the FLUOstar OPTIMA plate read-
er (BMG Labtech, Offenburg, Germany) which allowed the sequential
integration of light signals detected with two ﬁlter settings. The wave-
length of ﬁlter was set up according to the previous report (Rluc ﬁlter,
430 ± 30 nm; and EGFP ﬁlter, 535 ± 30 nm). The values were
corrected by subtracting the background BRET signals detected when
Rluc-mOX2αR was expressed alone. The BRET signal is calculated
using the ratio of 535 ± 30 nm emission over the 430 ± 30 nm emis-
sion for a cell sample containing only the Rluc construct which was
then subtracted from the same ratio for a sample containing the
interacting EGFP and Rluc fusion proteins and reported as mBRET(103× BRET ratio). The calculated BRET signals were plotted as a func-
tion of the total ﬂuorescence/luminescence ratios.
The BRET saturation assays could provide evidence for the speciﬁcity
of constitutive interactions. For BRET saturation curve experiments,
cells were transfected with a constant amount of plasmid with the
Rluc-tagged construct and increasing amounts of plasmid with the
EGFP-tagged construct. The total amount of plasmid DNAwas kept con-
stant by adding empty plasmid. Data were expressed as the net BRET
ratio, calculated as described above.
2.9. Western blot
Mice brain tissue and Neuro-2a cells were lysed in RIPA lysis buffer
(Beyotime, Shanghai, China) for Western Blotting using Mouse poly-
clonal to Orexin Receptor 2 (Abcam, Cambridge, UK) for mOX2R at pro-
tein level, β-actin (Abcam, Cambridge, UK) was used as loading control.
HEK293 cells in six-well plates were transfected with HA-mOX2αR
and/or Myc-mOX2βR. 48 h later, the cells were lysed with 1% RIPA
Lysis Buffer (Beyotime, Jiangsu, China). Ten micrograms of cell lysate
was separated by 10% SDS-PAGE and then transferred to a PVDF
membrane. The membrane was blocked with 5% milk, followed by an
overnight incubation at 4 °C with a primary rabbit polyclonal anti-HA
(Cell Signaling Technology, Danvers, USA) and anti-Myc (Cell Signaling
Technology, Danvers, USA) antibody, respectively. The membrane was
washed three times for 10 min in TBST and then incubated with a
goat anti-rabbit HRP secondary antibody. The membrane was washed
three times for 10 min in TBST and the bound antibody was detected
by chemiluminescence with the ECL Detection Reagent (Pierce, Rock-
ford, IL). As a control for loading, the same membranes were stripped
of antibody (Solarbio, Beijing, China) and reprobed with anti-β-actin
(Abcam, Cambridge, UK).
HEK293-mOX2αR/mOX2βR cells cultured in six-well plates were
grown to 70–80% conﬂuency. After overnight serum starvation, the
cells were treated with Orexin-A and Orexin-B ligands, respectively.
Then, the cells were washed twice with ice-cold PBS and were immedi-
ately lysed in RIPA lysis buffer.
The supernatants were collected, and protein concentration was de-
termined using the BCA Assay Kit (KeyGEN, Nanjing, China). Tenmicro-
grams of cell lysate was separated by 10% SDS-PAGE and then
transferred to a PVDF membrane. The membrane was blocked with 5%
milk, followed by an overnight incubation at 4 °C with a primary rabbit
polyclonal anti-phospho-ERK1/2 (Thr202/Tyr204) antibody (Cell Sig-
naling Technology, Danvers, USA). The membrane was washed three
times for 10 min in TBST and then incubated with a goat anti-rabbit
HRP secondary antibody. The membrane was washed three times for
10 min in TBST and the bound antibodywas detected by chemilumines-
cencewith the ECL Detection Reagent (Pierce, Rockford, IL). As a control
for loading, the same membranes were stripped of antibody (Solarbio,
Beijing, China) and reprobed with anti-total ERK1/2 (Cell Signaling
Technology, Danvers, USA).
2.10. Calcium ﬂuorescence measurement
Calcium signals were detected by suing Fluo-4NM Calcium Assay
Kits (Invitrogen, USA) following the manufacturer's instructions.
HEK293-mOX2αR, HEK293-mOX2βR and HEK293-mOX2αR/mOX2βR
cells were plated at 5 × 104 cells per well in a poly-D-lysine-coated
black 96-well plate and grown overnight, respectively. In addition,
HEK293 cells which were not transfected were used as control. Before
the assay, the cells were washed twice with assay buffer (1× HBSS,
20 mM HEPES). 100 μl of the dye loading solution was added to each
well of a 96-well plate. Cells were incubated at 37 °C in 5% CO2 humid-
iﬁed atmosphere for 30 min, then at room temperature for an addition-
al 30 min. The plates were washed three times with assay buffer to
remove excess dye. Subsequently, all cells were stimulated with
100 nM Orexin-A and Orexin-B, respectively. After stimulation, Ca2+-
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technologies, TriStar LB941, DLR ready (Germany) appropriate for exci-
tation at 485 nmand emission at 525 nm. The calcium ratio was mea-
sured by using the ﬂuorescence value after adding the agonist
taking away ﬂuorescence value before adding agonist divided by
the ﬂuorescence value before adding the agonist. The Protein Ki-
nase C Inhibitor Ro-31-8220 (50 nmol/l) (Cayman, USA) was used
to induce Ca2+. The peak increase in ﬂuorescence counts was re-
corded for each well. All the experiments were repeated three
times.2.11. SRE, CRE and NFAT-RE luciferase assay
For SRE, CRE and T-lymphocyte activation of nuclear factor-
responsive element (NFAT-RE) luciferase assay, HEK293-mOX2αR,
HEK293-mOX2βR, HEK293-mOX2αR/-mOX2βR or HEK293-
mOX2αR/mKOR cells were co-transfected with the plasmid of
pSRE-Luc (serum response element tagged with luciferase)
(PathDetect; Stratagene) or pCRE-Luc (cAMP-response element
tagged with luciferase) (PathDetect; Stratagene) or pGL4.30 (T-
lymphocyte activation of nuclear factor-responsive element with lu-
ciferase) (Promega) which contains ﬁreﬂy luciferase along with pRL-
Tk (Promega). pRL-TK vector is a Renilla luciferase construct used to
normalize data. Twenty-four hours after transfection, HEK293-
mOX2αR, HEK293-mOX2βR, HEK293-mOX2αR/-mOX2βR or
HEK293-mOX2αR/mKOR cells were treated with Orexin-A
(100 nM ﬁnal concentrations) or Orexin-B (100 nM ﬁnal concentra-
tion) as indicated for 6 h prior to harvest. In addition, HEK293-
mOX2αR/mOX2βR cells were pretreated with (PLC) inhibitor U-
73122 (10 μM for 30 min). The activities of ﬁreﬂy luciferase and
Renilla luciferase were measured by the Dual-Luciferase Reporter
(DLR) Assay System (Promega) with a FLUOstar OPTIMA (BMG
Labtech, Offenburg, Germany). The results were expressed as
mean ± SEM (standard error of the mean) from four independent
experiments performed in duplication. The ratio of ﬁreﬂy luciferase
luminescence signal to that of Renilla luciferase was determined.2.12. Cell proliferation assay
HEK293-mOX2αR/mOX2βR cells were seeded on a 96-well plate
at 1 × 104 cells per well in quadruplets. After 24 h, the cells were
treated by Orexin-A or Orexin-B for 24 h at the concentration of
1 nM, 10 nM and 100 nM, respectively. Cell proliferation was mea-
sured using a CCK-8 (Dojindo, Kumamoto, Japan) proliferation/via-
bility assay.
HEK293, HEK293-mOX2αR, HEK293-mOX2βR, HEK293-mOX2αR/
mOX2βR and HEK293-mOX2αR/mKOR cells were seeded in a 96-well
plate at 1 × 104 cells per well in quadruplets. After 24 h, all cells were
stimulated with 100 nM Orexin-A or Orexin-B for 24 h, respectively.
CCK-8 assay (Dojindo, Kumamoto, Japan) was performed according to
the manufacturer's instructions. Following incubation, the absorbance
of the suspension was measured at 450 nm. Each sample was run in
quadruplets. Non-seeded wells containing media alone were included
as a control.Fig. 1.The expression ofmOX2Rwas detectedusing a single cell PCR andWestern blotting.
(A) A single cell PCR to identify the cell containing mOX2αR and mOX2βR. The mice
neuroblastoma cell's cytoplasm was harvested via the patch clamp micro-electrode
pipette. The single-cell cDNA was synthesized and then ampliﬁed by RT-PCR. mOX2αR
and mOX2βR are co-express in a single cell. GAPDH was used as endogenous control for
RNA normalization. Lane marker: DNA marker; Lane-RT: The minus RT controls by omit-
ting reverse transcriptase was introduced to show the ampliﬁcation is not from genomic
DNA contamination; Lane mOX2αR: HEK293- mOX2αR cell lines; Lane mOX2βR:
HEK293-mOX2βR cell lines. (B) Western Blotting using speciﬁc antibody for mOX2R. In
mice brain tissue and Neuro-2a cell lysates, it was conﬁrmed the expression of mOX2R
at protein level. mOX2R appears to be expressed as 51 kDa bands.3. Statistical analysis
All the data are shown as themeans ± SEM. The datawere analyzed
using Microsoft Excel 2007 and GraphPad Prism v5.0. One-way ANOVA
was used for multiple group comparisons followed by a Tukey's test.
P b 0.05 was considered statistically signiﬁcant. All experiments were
repeated at least three times, and representative experiments are
shown in the ﬁgures.4. Results
4.1. The expression of mOX2αR and mOX2βR was detected in mice cells
In order to prove that mOX2αR andmOX2βRwere expressed in the
same cell, we conducted single-cell RT-PCR using the cell's cytoplasm of
the Neuro-2a cell. The results show that the receptor gene of mOX2αR
and mOX2βR was co-expressed in the detected single cell (Fig. 1A).
Due to the complex genomic organization of themouse OX2R splice
variants (mOX2αR/mOX2βR) and onlyminor differences between their
structures, there are no commercially antibodies available to distinguish
each one of the receptors [11]. Inmice brain tissue and Neuro-2a cell ly-
sates, Western blotting using speciﬁc antibody for mOX2R conﬁrmed
the expression of mOX2R at protein level. mOX2R appears to be
expressed as 51 kDa band (Fig. 1B).
4.2. Co-localization and co-expression of mOX2αR and mOX2βR in
HEK293-mOX2αR/mOX2βR cells
Co-localization assay was carried out in order to analyze whether
mOX2αR was associated with mOX2βR. HEK293 cells co-transfected
with plasmid expressing HA-mOX2αR, and Myc-mOX2βR was ﬁxed
and immunostained for both mOX2αR and mOX2βR. Confocal micros-
copy revealed a high degree co-localization of mOX2αR and mOX2βR,
predominantly to the plasma membrane, while the location of nuclear
was visualized by DAPI (Fig. 2A).
To examine cell surface expression of mOX2αR and mOX2βR, ELISA
assay was carried out by using anti-HA and anti-Myc antibody, respec-
tively. Two fusion proteins HA-mOX2αR and Myc-mOX2βR which
were N-terminally epitope-tagged with HA or Myc tags were detected.
After co-expression in HEK293, it was found that the cell surface
Fig. 2. Co-localization and co-expression of mOX2αR and mOX2βR in HEK293 cells transfected with plasmids expressing HA-mOX2αR and Myc-mOX2βR. (A) Confocal anal-
ysis of co-localization of mOX2αR andmOX2βR. HEK293 cells co-transfected with HA-mOX2αR andMyc-mOX2βR were ﬁxed and immunostained with anti-HA and anti-Myc
antibodies to detect mOX2αR and mOX2βR, respectively. Confocal images of mOX2αR and mOX2βR were merged to show regions of co-localization. DAPI was used to stain
the nuclear. (B) Determination of cell surface expression of HA-mOX2αR and Myc-mOX2βR. ELISA assay was conducted on intact cells using anti-HA and anti-Myc antibody,
respectively. HA-tagged mOX2αR and Myc-taggedmOX2βR were transfected alone or together, as illustrated in the ﬁgure. Values are means ± SEM of triplicate determina-
tion. (C) Co-expression of HA-mOX2αR and Myc-mOX2βR was conﬁrmed by Western Blotting analysis. The expression of HA-mOX2αR was found in HEK293 cells
transfected with plasmid(s) HA-mOX2αR and HA-mOX2αR/Myc-mOX2βR and Myc-mOX2βR was detected in HEK293 cells transfected with plasmid(s) Myc-mOX2βR
and HA-mOX2αR/Myc-mOX2βR. β-Actin was used as loading control. 1. HA-mOX2αR; 2. Myc-mOX2βR; 3. HA-mOX2αR/Myc-mOX2βR.
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mOX2αR/mOX2βR heterodimer (Fig. 2B). Western blotting provided
conclusive evidence that HA-mOX2αR was detected in HEK293-
mOX2αR cell lines and HEK293-mOX2αR/mOX2βR cell lines, and the
expression of Myc-mOX2βR was detected in HEK293-mOX2βR cell
lines and HEK293-mOX2αR/mOX2βR cell lines. It showed that HA-
mOX2αR and Myc-mOX2βR were co-expressed in HEK293-mOX2αR/
mOX2βR cell lines (Fig. 2C). The result from Fig. 2B showed that the ex-
pression level of mOX2αR and mOX2βR did not change by co-
expression.4.3. Heterodimerization of mOX2αR and mOX2βR determined by Co-
immunoprecipitation (Co-IP) and BRET
Co-IP analysis was used to identify the interaction between two re-
ceptors in the formation of heterodimer. After co-expression in
HEK293 cells of HA-mOX2αR/Myc-mOX2βR, immunoprecipitation
with anti-Myc antibodies resulted in the presence of anti-HA immuno-
reactivity in the precipitate. SDS-PAGE demonstrated the presence of
bands identiﬁed by the Myc antibody (Fig. 3A), consistent with mono-
meric form of the HA-mOX2βR receptor. This result showed that
Fig. 3. Heterodimerization of mOX2αR with mOX2βR by co-immunoprecipitation (Co-IP) analysis. (A) HEK293 cells were transfected with expression vectors of both HA-mOX2αR and
Myc-mOX2βR fusion proteins (co-transfected) or with either vector alone. Samples containing either HA-mOX2αR or Myc-mOX2βR were alsomixed (Mix). Conﬁrmation of the expres-
sion of appropriate constructs was obtained by immunoblotting cell lysates with either anti-Myc or anti-HA antibodies (lower panels). The cell lysates were subsequently
immunoprecipitated (IP) with anti-HA antibody and immunoblotted with anti-Myc antibodies (upper panel) and anti-HA antibodies (lower panels), respectively. (B) HEK293 cells
were transfected to express HA- orMyc- tagged fusion proteins as indicated. The cell lysateswere subsequently incubatedwith anti-HA antibody and protein G-Sepharose beads followed
by immunoblotted with anti-Myc antibody and anti-HA antibody, respectively.
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taneously.Meanwhile,we also tested the homodimerization ofmOX2αR
and mOX2βR. The results show that there is no precipitated tagged fu-
sion proteins being detected when expressing the same kind of
mOX2αR or mOX2βR alone. Besides, the pair of mOX2αR and KOR was
also conﬁrmed as negative control by using Co-immunoprecipitation
(Fig. 3B).
To conﬁrm the heterodimerization, BRET analysis was performed.
HEK293 cells were transiently co-transfected with plasmids expressing
Rluc-tagging or EGFP-tagging construct. Twenty four hours after trans-
fection, BRET ratio was measured in the living cells. As a result,
compared with the cell transfected with Rluc-mOX2αR alone or co-
transfected with plasmid pair Rluc and EGFP-mOX2βR, EGFP and Rluc-
mOX2αR, Rluc-mOX2αR and EGFP-mOX2αR, Rluc-mOX2βR and
EGFP-mOX2βR, or Rluc-mOX2αR and EGFP-KOR, the BRET ratio in
EGFP-mOX2βR and Rluc-mOX2αR co-transfected group was signiﬁ-
cantly increased (Fig. 4A), which indicates the constitutive association
of mOX2αR andmOX2βR. To further investigate whether this constitu-
tive association ofmOX2αR andmOX2βR is speciﬁc or not, BRET satura-
tion assays were performed. By constructing a BRET saturation curve,
HEK293 cells were co-transfected with a constant amount of the Rluc
construct while increasing concentrations of the EGFP tagged plasmid.
As a result, a positive BRET signal for the transfer of energy between
mOX2αR-Rluc andmOX2βR-EGFPwas obtained (Fig. 4B). The BRET sig-
nal increased as a hyperbolic function of the concentration of the EGFP-
fusion construct added (assessed by the ﬂuorescence emitted upon di-
rect excitation at 480 nm) reaching an asymptote. As the paired EGFP
and Rluc-mOX2αR, EGFP-mOX2βR- and Rluc, EGFP-mOX2αR and
Rluc-mOX2αR, EGFP-mOX2βR and Rluc-mOX2βR, led to an ﬂatten
BRET signal (Fig. 4B), the hyperbolic BRET signal found in the cells
expressing Rluc-mOX2αRand EGFP-mOX2βR indicates that the interac-
tion between mOX2αR and mOX2βR is speciﬁc. Meanwhile, it alsoprovided the evidence to support that mOX2αR and mOX2βR do not
form homodimerization. To further determine whether the ligands for
the two receptors can modulate the receptor heterodimerization,
BRET analyses were performed in the presence of Orexin-A or Orexin-
B. When HEK293 cells coexpressing mOX2αR-Rluc and mOX2βR-
EGFP were treated with Orexin-A or Orexin-B at 100 nM for 15 min,
there was a dramatic increase in BRET ratio, moreover, the BRET ratio
was signiﬁcantly increased by combination treatment with Orexin-A
and Orexin-B than treatment with Orexin-A or Orexin-B alone
(Fig. 4C). BRET association analysis conﬁrmed the increased receptor
heterodimerization by Orexin-A and/or Orexin-B stimulation. Together,
Co-IP and BRET assays conﬁrmed the heterodimerization between
mOX2αR and mOX2βR.4.4. Orexin-A or Orexin-B induced enhanced ERK1/2 activation in the
HEK293-mOX2αR/mOX2βR cells
We examined whether the heterodimer could affect cell signal
transduction. HEK293-mOX2αR/mOX2βR cells were treated with
100 nMof Orexin-A or Orexin-B for 0–60 min for time dependent stud-
ies and treated with different concentrations of Orexin-A or Orexin-B
(0.01–100 nM) for 5 min for dose dependent experiments.
The effect of Orexin-A and Orexin-B on ERK1/2 activation was found
to be both time- and dose-dependent (Fig. 5A and B). Themaximal level
of ERK1/2 activation (about 4.37 fold increase in ERK1/2 phosphoryla-
tion)was achieved byOrexin-A (100 nM) induction at 5 min post-stim-
ulation. The ERK1/2 activation remained signiﬁcant until 30 min
(P b 0.001), and returned to near basal level at 60 min (Fig. 5A). A
similar induction of ERK1/2 phosphorylation was observed by the addi-
tion of 100 nM Orexin-B, which induced a 7.14 fold increase compared
with HEK293 cells in the peak level at 5 min (Fig. 5A). Although Orexin-
Fig. 4. Heterodimerization of mOX2αR with mOX2βR by BRET analysis in living cells. (A) Heterodimerization of mOX2αR with mOX2βR was measured in the seven indicated different
conditions by BRET. Twenty-four hours after transfection, both ﬂuorescence and luminescence of each sample were measured prior to every experiment to conﬁrm equal expression
of Rluc whilemonitoring the increase of EGFP expression. BRET ratiowas detected and showed bymBRET (mBRET = BRET ratio × 1000). All the results were expressed asmean ± SEM
of four experiments, $P b 0.05 vs. Rluc-mOX2αR goup; #P b 0.05 vs. Rluc-mOX2αR/EGFP group; **P b 0.01 vs. Rluc/EGFP-mOX2βR group. (B) BRET saturation assay. HEK293
cells were transfected with constant amount of Rluc construct and increasing amounts of EGFP construct. The calculated BRET signals were plotted as a function of the total ﬂuorescence/
luminescence ratios, and data was analyzed using linear and non-linear regression curve ﬁtting in GraphPad Prism (GraphPad Software, CA, USA). (C) Effects of Orexin-A and/or Orexin-B
on BRET ratio. HEK293 cells were transiently co-transfected with Rluc-mOX2αR and EGFP-mOX2βR (1:3). Twenty-four hours after transfection, previous addition of Rluc substrate
Coelenterazine-h for 5 min, cells were treated or not with Orexin-A and/or Orexin-B for 5 min, BRET ratio mBRET was analyzed by BRET. All the results were expressed as mean ± SEM of
four experiments. *P b 0.05, **P b 0.01 vs. control group.
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failed to reach signiﬁcance.
As for dose-dependent ERK1/2 activation, we observed that both
Orexin-A and -B induced a dose-dependent (0.01–100 nM) increase in
ERK1/2 phosphorylation with a maximal response at 100 nM (Fig. 5B;
P b 0.01). ERK1/2 activation was signiﬁcantly higher stimulated by
Orexin-B with 7.59 fold increase at peak level (100 nM treatment)
than the Orexin-A with 6.73 fold increase at peak level (100 nM treat-
ment) (Fig. 5A and B). Interestingly, Orexin-B at 10 nM induced a
much more pronounced rise in ERK1/2 activation than Orexin-A
(Fig. 5B; P b 0.01).
The degree of ERK1/2 phosphorylation was compared in single
transfected cells and in double transfected cells which were treated
with Orexin-A or Orexin-B (1–100 nM) for 5 min, respectively. The
results were showed in Fig. 5C. ERK1/2 phosphorylation levels showed
a signiﬁcant difference in single transfected cells which were treated
with Orexin-A or Orexin-B at the concentration of 100 nM. However,
ERK1/2 phosphorylation in double transfected cells appeared at
the concentration of 10 nM. The above results showed that theheterodimerization of mOX2αR and mOX2βR induced by Orexin-A or
Orexin-B could enhance ERK1/2 activation.
4.5. Calcium signal studies
To investigate the effects of Orexin-A and Orexin-B onmOX2αR and
mOX2βR receptor heterodimer, we looked at the change in intracellular
Ca2+. In this study, we used HEK293 cell lines co-expressing mOX2αR
and mOX2βR, expressing only mOX2αR and only mOX2βR as cell
models. The results showed that both Orexin-A and Orexin-B were
able to rapidly elevate intracellular Ca2+ in a very short time
(P b 0.001). Notably, as shown in Fig. 6A, Orexin-A and Orexin-B exclu-
sively exhibited 1.92 and2.78 foldmore potent Ca2+mobilization in the
HEK293 cells expressing mOX2αR and mOX2βR respectively than in
the cells expressing mOX2αR or mOX2βR alone. Furthermore, the
level of intracellular Ca2+ was increased more by Orexin-B induction
than by Orexin-A (P b 0.001), which was consistent with the results
fromdose-dependent ERK1/2 activation byWestern blot analysis. In ad-
dition, there was almost no change after the stimulation in the control
Fig. 5. ERK1/2 phosphorylation. (A) Time-dependent ERK1/2 phosphorylation. HEK293- mOX2αR/mOX2βR cell lines were treated with Orexin-A (100 nM) or Orexin-B (100 nM) for
0 min, 5 min, 10 min, 15 min, 30 min and 60 min (a). The time-dependent effects of the two treats were quantiﬁed and shown (b). (B) Dose-dependent ERK1/2 phosphorylation.
HEK293-mOX2αR/mOX2βR cell lines were treated with Orexin-A or Orexin-B (0.01–100 nM) for 5 min (a). The dose-dependent curve of the two treats was quantiﬁed and showed
(b). (C) ERK1/2 phosphorylation in HEK293-mOX2αR, HEK293-mOX2βR and HEK293-mOX2αR/mOX2βR cell lines. HEK293-mOX2αR, HEK293-mOX2αR and HEK293-mOX2αR/
mOX2βR cells were treated with Orexin-A or Orexin-B (1–100 nM) for 5 min (a). The dose-dependent curve of the three cell groups was quantiﬁed and shown (b). Western blots
were compared phospho-ERK1/2 with total ERK1/2 in cell lines treatedwith Orexin-A or Orexin-B. The densities of the bands corresponding to 44 kDa and 42 kDa for ERK1/2 were quan-
tiﬁedwith an imaging densitometer (Scion Image). The data represent themean ± SEM of threemeasurements from three independent experiments. *P b 0.05, **P b 0.01, ***P b 0.001
compared to basal.
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that PKC Inhibitor (Ro-31-8220) can signiﬁcantly inhibit the release of
Ca2+, indicating that intracellular calcium elevation relies on PKC acti-
vation.We also found that the intracellular Ca2+ dramatically increased
in 20 s after stimulation and reached a plateau after around 80 s (Fig. 6C
and D).4.6. Orexin-A or Orexin-B enhanced SRE and decreased CRE activation de-
pending upon PKC activity and PKA activity in HEK293-mOX2αR/
mOX2βR cells
To study and characterize G protein coupling proﬁle ofmOX2αR and
mOX2βR, we used reporter gene assays to detect downstream signal
SRE (MAP kinase pathway activated by Gβγ subunits) and CRE (PKA-
speciﬁc reporter) in HEK293-mOX2αR, HEK293-mOX2βR, HEK293-
mOX2αR/mOX2βR and HEK293-mOX2αR/mKOR cells. As a result, the
SRE-luc activity was signiﬁcantly increased (Fig. 7A) whereas the CRE-luc activity was signiﬁcantly decreased in all the treated cells (Fig. 7B).
Moreover, compared with HEK293-mOX2αR and HEK293-mOX2βR,
the SRE-luc activity was signiﬁcantly increased (P b 0.05, Fig. 7A)
whereas the CRE-luc activity was signiﬁcantly decreased (P b 0.01,
Fig. 7B) in the HEK293-mOX2αR/mOX2βR cells. These results showed
that heterodimerization of mOX2αR and mOX2βR increased SRE and
decreased CRE response element activity depending on PKC activity
and PKA activity when Orexin-A or Orexin-B was added to HEK293-
mOX2αR/mOX2βR cells.4.7. Orexin-A or Orexin-B enhanced NFAT-RE signal pathway depending
upon NFAT-RE activity in HEK293-mOX2αR/mOX2βR cells
Increasing evidence indicates that the heterodimer (oligodimers) of
receptors could activate several signal pathways. The above results
showed that the dimerization of mOX2αR and mOX2βR can affect the
activities of the signal pathways of CRE and SRE, respectively. Owing
Fig. 6. Intracellular Ca2+ was elevated when mOX2αR and mOX2βR were co-expressed in HEK293 cells. (A) Intracellular Ca2+ was detected by suing Fluo-4NM Calcium Assay Kits. The
ﬁrst peak increase in ﬂuorescence counts was recorded for each cell line and analyzed. The results showed that Orexin-A or Orexin-B elevated intracellular Ca2+ in very short times
(***P b 0.001) in doubled transfected cell lines, compared to cells single expressed mOX2αR, mOX2βR or untransfected cells as control. (B) Protein Kinase C Inhibitor (Ro-31-8220)
induces Ca2+ decreased. Protein Kinase C Inhibitor was ﬁrst added in HEK293-mOX2αR/mOX2βR cell lines and then the cell lines were stimulated. The results showed that Intracellular
Ca2+ decreased (C and D). The variation of intracellular Ca2+ is about 180 s. The peak increase in ﬂuorescence counts was recorded for 20 second intervals. The results showed that the
intracellular Ca2+ slowly decreased after the peak point and gradually up to a relative value. All data represent the mean ± SEM of three measurements from three independent exper-
iments. *P b 0.05, **P b 0.01, ***P b 0.001.
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Ca2+ mobilization which was evoked by NFAT-RE signal pathway,
we subsequently detected NFAT-RE activity using NFAT-RE luciferase
reporter assay. Our results indicated that NFAT-RE activity in
mOX2αR/mOX2βR cells treated byOrexin-Awas signiﬁcantly increased
(P b 0.05, Fig. 7C), compared withmOX2αR ormOX2βR groups treated
by Orexin-A. The NFAT-RE activity stimulated by Orexin-B was similar
to Orexin-A (P b 0.05, Fig. 7C). Therefore, the dimerization of
mOX2αR and mOX2βR enhanced the activity of NFAT-RE.
In addition, after HEK293-mOX2αR/mOX2βR cell was pretreated
with PLC inhibitor U-73122, the NFAT-RE activity was completely abro-
gated by PLC inhibitor in double transfected cells, suggesting that
Orexin-A and Orexin-B induced enhanced NFAT-RE activation depends
upon Gq/PLC pathways.
4.8. Orexin-A and Orexin-B induced enhanced proliferation of HEK293-
mOX2αR/mOX2βR cell lines
This study indicates that mOX2αR and mOX2βR form heterodimer,
synergistically increasing cell signal transduction. Next, we decided to
investigate whether these changes are related to cell function.
As anticipated, Fig. 8A shows a signiﬁcant cell proliferative effect of
both Orexin-A and -B on HEK293-mOX2αR/mOX2βR after 24 h expo-
sure. For both Orexins, this functional outcome of mOX2αR/mOX2βR
co-expression followed a dose-dependent pattern reaching signiﬁcance
at 10 nM (P b 0.01). Fig. 8B shows that the treatment with Orexin-A at
100 nM for 24 h resulted in a signiﬁcant increase in the proliferation of
HEK293-mOX2αR/mOR2βR expressing cells compared to cells only
expressing HEK293-mOX2αR, HEK293-mOX2βR and negative control
HEK293-mOX2αR/mKOR which could not form heterodimer between
mOX2αR with mKOR (P b 0.01). When treated with Orexin-B, the
results were similar to that of Orexin-A. In HEK293 cells, there were
no signiﬁcant proliferative responses to Orexin-A or Orexin-B.5. Discussion
GPCRs have complex physiological roles and itsmalfunction is close-
ly related tomany diseases [28]. GPCR dimers exhibit speciﬁc functional
properties, such as agonist recognition, signaling, and trafﬁcking
[13,18].
Our experiments using single cell RT-PCR and confocal microscopy
revealed a co-expression and high degree of co-localization of
mOX2αR with mOX2βR, predominantly on the plasma membrane in
agreement with their predicted seven trans-membrane domain topolo-
gy. Using ELISA assays, we determined that HA-mOX2αR and Myc-
mOX2βR expression on cell surface was not signiﬁcantly changed in
mOX2αR/mOX2βR co-expressing HEK293 cells compared to single
transfected cells. These results demonstrated that co-expression of
mOX2αR andmOX2βRhad no effect onmOX2αR andmOX2βR cell sur-
face targeting.
Notably up to now, heterodimerization of mOX2αR with mOX2βR
has not been reported. Using Co-IP technologies, we conﬁrmed that
mOX2αRwithmOX2βR can reliably form a heteroduplex. BRET analysis
further conﬁrmed heterodimerization between mOX2αR with
mOX2βR. BRET analysis also indicated constitutive interactions
between these two GPCRs, and BRET saturation assay proved that the
association was speciﬁc. Furthermore, BRET association analysis con-
ﬁrmed the increased receptor heterodimerization following Orexin-A
or Orexin-B treatment. More interestingly, both Co-IP assay and BRET
assay could not detect the homodimerization of both mOX2αR and
mOX2βR, suggesting that the difference between mOX2αR and
mOX2βR play an important role in their interaction. mOX2αR and
mOX2βR only differ by 17amino acids at their C-terminus. Thus, we
believe their C-terminus might involve in the mediation of
heterodimerization, which could be tested by point mutant in the fu-
ture. GPCR dimerization has been demonstrated mainly through trans-
membrane domain 3 and transmembrane domain 4 [20]. However, a
Fig. 7. Regulation of SRE, CRE and NFAT-RE activities. Twenty-four hours after transfection
with pSRE-luc (A) or pCRE-luc (B) or pNFAT-RE-luc (C) along with pRL-Tk, HEK293-
mOX2αR, HEK293-mOX2βR, HEK293-mOX2αR/mOX2βR and HEK293-mOX2αR/mKOR
cells were treated with Orexin-A (100 nM ﬁnal concentration) or Orexin-B (100 nM
ﬁnal concentration) as indicated for 6 h prior to harvest. In addition, HEK293-mOX2αR/
mOX2βR cell was pretreatedwith (PLC) inhibitor U-73122 (10 μM for 30 min). The ﬁreﬂy
and Renilla luciferase activity was assayed using the Dual-Luciferase® Reporter Assay
System according to the manufacturer's instructions. The ratio of ﬁreﬂy luciferase lumi-
nescence signal to that of Renilla luciferase was determined. The results were expressed
as means ± SEM from four independent experiments performed in duplicates.*P b 0.05,
**P b 0.01.
Fig. 8. Proliferation of transfected cell lines in response to Orexin-A/-B. (A) Dose-
dependent effects of Orexin-A/-B on HEK293-mOX2αR/mOX2βR cell proliferation after
24 h as determined by a CCK-8 proliferation/viability assay. HEK293-mOX2αR/mOX2βR
cells were cultured for 24 h 96 wells (1 × 104 cells per well in quadruplet) prior to treat-
ment with Orexin-A/-B at 1 nM, 10 nM and 100 nM, respectively, and starved overnight
in serum free media. Cell proliferation was measured using a CCK-8 proliferation/viability
assay. Double transfected cells which were not treated by Orexin-A/-B were controls. (B)
Proliferation of HEK293-mOX2αR/mOX2βR cell lines in response to Orexin-A/-B. HEK293,
HEK293-mOX2αR, HEK29-mOX2βR, HEK293-mOX2αR/mOX2βR or HEK293-mOX2αR/
mKOR cell lines were cultured for 24 h in 96 wells prior to treatment with Orexin-A/-B
at 100 nM and starved overnight in serum free media. Cell proliferation was measured
as above. The proliferation of HEK293-mOX2αR/mOX2βR cellswas enhanced signiﬁcantly
at 24 h post-stimulation, compared with cells of HEK293-mOX2αR, HEK293-mOX2βR
and HEK293-mOX2αR/mKOR cells. Untransfected HEK293 cells were control. Data points
were determined from three independent experiments each performed in quadruplicate
samples. ***P b 0.001, **P b 0.01.
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the dimerization of GPCR including extracellular N-terminal domain
[39], extracellular Cys residues [49] and also C-terminal domain
[15,19]. Here, we got a similar result as Svetlana Cvejic, who showed
that the mutant δ-opioid receptor, with a 15-residue C-terminal
deletion, does not exhibit dimerization [15]. Therefore, some, if not all,
of GPCR dimerization might be mediated by their C-terminal domain.
The response of cells to external stimuli is mediated by the signal
transduction system. Various extracellular signal molecules bind with
the corresponding target receptors, followed by initiation of the cell
signal transduction cascade. There has beenmorewidespread reporting
of GPCR dimerization affecting the signal transduction [24,35,36]. For
example, the heterodimerization of APJ with KOR leads to the increase
of ERK1/2 activation evoked by apelin-13 or DynA (1–13) [22]. Similar-
ly, heterodimerization of OX1R with the cannabinoid receptor CB1 acti-
vated the mitogen-activated protein kinase pathway [46].
Orexins induce a rapid, dose-dependent increase in activation of
ERK1/2 and p38 MAPK in a variety of cell lines and tissues [3,21]. Weexplored the possibility that the heterodimer of mOX2αR/mOX2βR
can acquire novel signal transduction characteristics. When HEK293-
mOX2αR/mOX2βR cells were treated with Orexin-A or Orexin-B, the
ERK1/2 phosphorylation also showed a time-dependent and dose-
dependent increase. Our data are in agreement with previous studies
where maximal ERK1/2 activation was achieved by Orexin-A/-B at
concentrations of 100 nM and from 5 min and sustained up to 60 min
after stimulation [4,13,17,21]. Furthermore, compared with single
transfected cells and double transfected cells which were treated with
Orexins (1–100 nM) for 5 min, a signiﬁcant ERK1/2 phosphorylation
was achieved in double transfected cells at much lower concentration
(10 nM vs. 100 nM).
Since PKC lies upstream of ERK1/2 phosphorylation in Orexin-A and
-B stimulated cells [18,27,47], we further propose that the mOX2αR/
mOX2βR heterodimer might also affect the PKC pathway. To conﬁrm
this hypothesis, we investigated the alteration of the two speciﬁc func-
tional elements of transcriptional regulators including SRE and CRE. SRE
can be activated via the PKC pathway, and CRE-luc reporter systems are
useful tools for discriminating AC/PKA and PLC/PKC signaling pathways
[37,42]. Consistentwith the increase in ERK1/2 phosphorylation, the SRE-
luc (PKC-speciﬁc reporter) activity was signiﬁcantly increased whereas
the CRE-luc (PKA-speciﬁc reporter) activity was signiﬁcantly decreased
in the HEK293-mOX2αR/mOX2βR cells compared with HEK293-
mOX2αR or HEK293-mOX2βR cells. Indeed, heterodimerization of R1
with R4 (an orphan receptor paralog) induced ERK1/2 phosphorylation
mainly via activation of PKCs [40]. Our experiment suggests that ERK l/2
activation stimulated by heterodimerization depends on the activation
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phorylation of target protein, to launch a series of physiological and bio-
chemical reactions.
There is also evidence that dimerization can affect the PLC/Ca2+ re-
sponses. Dimerization of FP and altFP4 receptor, which was stimulated
by prostaglandin F2a (PGF2a), elicited a rapid increase in intracellular
Ca2+ followed by a steady state phase in HEK293/EBNA cells co-
expressing FP and altFP4 receptor variants [29]. Activation of OX1R
and OX2R by Orexins results in target cell activation, generally reﬂected
in increased intracellular Ca2+ levels and postsynaptic excitation that
can last several minutes [30,45]. In recombinant systems, activation of
OX1R or OX2R receptor results in a receptor-operated Ca2+ inﬂux and
elevation of intracellular Ca2+ concentrations [32]. In addition, in rat hy-
pothalamic cultures, Orexins cause PKC-mediated Ca2+ inﬂux [30]. In
this study, both Orexin-A and Orexin-B were able to rapidly elevate in-
tracellular Ca2+ in a very short time in HEK293-mOX2αR/mOX2βR cell
lines, which was consistent with the above results. Furthermore, based
on serial measurements six times, we found that intracellular Ca2+ rap-
idly reached the maximum level after stimulation by agonists, then de-
creased slowly, gradually achieving a relatively stable value.
It has been reported that dimerization of GPCRs can alter the cou-
pling to G protein α-subunits. For example, dimerization of CB1 and
D2 receptor can result in switching of G-protein coupling from Gs to
Gi [26]. In this study, we also used the reporter gene systems to test
this possibility. Although the heterodimerization mOX2αR with
mOX2βR could not alter the coupling to G proteins; it enhanced the
coupling with Gq α-subunit. Subsequently, heterodimerization
mOX2αR with mOX2βR could elevate intracellular Ca2+. This increase
was abolished by the addition of PLC inhibitor, U-73122, indicating
that Orexin-A and Orexin-B induced enhanced NFAT-RE activation de-
pends upon a distinct Gq/PLCpathway. It has been reported that the his-
tamineH1 receptor and the 1b-adrenoreceptor also elevate intracellular
Ca2+ via activation of Gq/G11 [8]. The alternative splicing is one of the
importantmethods for GPCR regulationwhichhas formed the complex-
ity and diversity of the GPCR regulation. The mOX2αR and mOX2βR of
mouse are good examples.
MAPK signaling pathways play an important role in the regulation of
cell growth, differentiation and gene expression. It has been reported
that ERK1/2 phosphorylation induced by OX1R activation may protect
from cell death [4]. ERK1/2 activation by Orexins exerts proliferative ef-
fects in HEK293-OX2R expressing OX2R [46]. In rat adrenocortical cells,
ERK1/2 and p38 MAPK pathways stimulated by OX2R appear to modu-
late cell growth [43]. To further explore whether the heterodimer of
mOX2αR with mOX2βR affects the cell viability, cell proliferation was
investigated. Following treatment with Orexins, the proliferation of
HEK293-mOX2αR/mOX2βR cells was signiﬁcantly increased compared
with HEK293-mOX2αR or HEK293-mOX2βR cells (controls).
How do these ﬁndings translate to humans? Interestingly, compari-
son of the complete amino acid sequence for all themOXRcDNAs to that
of the human and rat homologs, revealed a high degree of sequence
identity, indicating that these receptor genes are highly conserved be-
tween these species [11]. Furthermore, according to the results we ob-
tained from ClustalX2 and MEGA5 (software used for evolution
analysis), we found that the OX2Rβ in the mouse (mOX2Rβ; 460aa)
compared to mOX2Rα (443aa), is much more close to the OX2R gene
in rat (460aa); meanwhile, OX2α revels more conservation to human
OX2 receptor (444aa). Acquiring an alternatively spliced exon is associ-
ated with an increased rate of evolution in the constitutive exons of a
gene [14]. This is of interest as the mOX2Rβ has 8 exons and the
mOX2Rα 7 exons, which may be a consequence during the evolution;
hence, the ﬁnding of heterodimerization between mOX2Rα and
mOX2Rβmight provide a newand differentway to investigate the func-
tion and evolution of the OX2 receptor. Moreover, the diversity of the
GPCR superfamily is based upon splice variants. However, to date no
one has successfully identiﬁed a human splice variant of OX2β. Howev-
er, future studies should concentrate sequencing OX2R in a widerepertoire of human tissues, as it can be expressed in a tissue-speciﬁc
manner, or the levels might be extremely low.
In conclusion,we report for theﬁrst time thatmouseOX2αR forms a
heterodimer with OX2βR. This heterodimerization process drives acti-
vation o PKA and PKC-signaling pathways upon activation by Orexins.
Furthermore, intracellular Ca2+ via activation of Gqwas elevated rapid-
ly after stimulation by corresponding agonists, and cell proliferation
was also signiﬁcantly increased. However, the molecular mechanism
of dimerization is still not clear, including binding site combination. Fu-
ture directions should focus on the structural characteristics of the het-
erodimer and the physiological consequences ofmOX2αR andmOX2βR
heterodimerization.
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